Epimagnolin A exhibits significant anti-inflammatory, anti-viral, and anti-cancer properties, making it a compound of interest in pharmaceutical research. It has been studied for its ability to inhibit the production of pro-inflammatory cytokines and suppress NF-κB signaling, a key pathway involved in inflammation and tumor progression. It also demonstrates anti-viral activity, particularly against influenza virus, by inhibiting viral replication and spread in host cells, positioning it as a potential lead for antiviral drug development. In cancer research, Epimagnolin A shows inhibitory effects on the proliferation of various human cancer cell lines, particularly lung and breast cancer cells, by inducing cell cycle arrest and apoptosis. Additionally, it demonstrates potential as a natural compound for developing chemopreventive agents due to its antioxidant activity and low toxicity in normal cells. Its presence in certain medicinal plants supports its use in traditional medicine for treating inflammatory conditions. Research remains in preclinical stages and is not yet applied clinically.